WebLocation: Basel Area, Switzerland. Founder/ CEO of ADV Life Science SA. CEO of Inotrem SA. A senior executive with a broad R&D experience in the pharmaceutical industry. Most recently Executive VP Head of Pharma Research and Early Development at Roche (2010 to 2012) Executive VP Head of Development and Chief Medical Officer at Roche (2007 to … WebINATHERYS (Evry Cedex, FR) International Classes: C07K16/28. View Patent Images: Download PDF 20240119543 . Primary Examiner: CENTRAL, DOCKET . Attorney, Agent or Firm: W&C IP (Reston, VA, US) Claims: 1. An isolated anti-TfR antibody or a protein with an antigen-binding portion of an anti-TfR antibody, comprising either, (a) a variable heavy ...
Research programme: anti-CD89 monoclonal antibody
WebAt a glance Originator Inatherys Class Monoclonal antibodies Mechanism of Action Fc receptor modulators Orphan Drug Status No New Molecular Entity Yes Highest … WebMore than 20 years of experience in R&D project and portfolio management in the Pharma and Biotech industries. Scientific expertise in metabolic diseases (including NAFLD/NASH) and in the Nuclear Receptor field. COO and Member of the board at Genfit. Various positions in the department of Gene Therapy of Aventis both in France and in the US. east gippsland football fixture
Jean-Jacques Garaud, CEO, Inotrem
WebInatherys is a biotechnology company developing monoclonal antibodies for therapies for cancers and severe inflammatory diseases resistant to conventional treatment. INA03 … WebAssignee: INATHERYS Inventors: Pierre Launay, Coralie Belanger, Hervé Souchet USE OF THE CD71 RECEPTOR IN THE PROGNOSIS AND TREATMENT OF ENDOMETRIOSIS. Publication number: 20240352415 Abstract: The ... WebInatherys is a biotechnology solutions company. Use the CB Insights Platform to explore Inatherys's full profile. Inatherys - Headquarters Locations, Products, Competitors, Financials, Employees east gippsland galaxias